News
CTMX
1.710
-1.72%
-0.030
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Benzinga · 11/18 10:14
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 11/17 18:20
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 11/17 17:32
Mullen (MULN) Stock Pops 4% on ELMS Funding News
Investor Place · 11/17 16:39
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
Benzinga · 11/17 16:14
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
Investor Place · 11/17 15:47
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/17 13:07
Regeneron And CytomX Announce Strategic Research Collaboration In The Field Of Conditional Bispecific Therapeutics For The Treatment Of Cancer
Benzinga · 11/17 12:05
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Benzinga · 11/14 13:21
BMO Capital Downgrades CytomX Therapeutics to Market Perform, Lowers Price Target to $2.6
Benzinga · 11/14 11:19
--BMO Capital Downgrades CytomX Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2.60 From $3
--BMO Capital Downgrades CytomX Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2.60 From $3
MT Newswires · 11/14 08:20
JP Morgan Downgrades CytomX Therapeutics to Underweight
Benzinga · 11/10 09:47
--JPMorgan Downgrades CytomX Therapeutics to Underweight From Overweight
--JPMorgan Downgrades CytomX Therapeutics to Underweight From Overweight
MT Newswires · 11/10 08:10
BRIEF-CytomX Therapeutics Reports Q3 2022 Results
Reuters · 11/08 22:43
CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 22:35
CytomX GAAP EPS of -$0.35 misses by $0.05, revenue of $16.92M misses by $3.13M
Seekingalpha · 11/08 22:11
CytomX Therapeutics Q3 EPS $(0.35) Misses $(0.31) Estimate, Sales $16.91M Miss $17.94M Estimate
Benzinga · 11/08 21:33
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- Advancing wholly owned, next-generation conditionally activated therapeuticsCX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 - - CX-904, Company’s first clinical stage Probody T-cell bispecific (EFGRxCD3), cont...
GlobeNewswire · 11/08 21:10
-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q3 Revenue $16.9M, vs. Street Est of $20.1M
-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q3 Revenue $16.9M, vs. Street Est of $20.1M
MT Newswires · 11/08 16:45
CytomX Therapeutics To Present Preclinical Data For Conditionally Activated Interferon Alpha-2b At The SITC 2022 Annual Meeting
Benzinga · 11/07 21:29
More
Webull provides a variety of real-time CTMX stock news. You can receive the latest news about Cytomx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company's product candidates include the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX2009, targeting CD166) and CX-2029, targeting CD71, and the Probody immune checkpoint inhibitors pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4). It also has two preclinical agents in investigational new drug (IND)-enabling studies - a conditionally activated ADC targeting EpCAM/Trop-1 (CX-2043) and a conditionally activated T-cell engaging bispecific antibody targeting EGFR and CD3 (CX-904).